VCEL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 111375 min ago

@ $47.14

Išleistas: 14 vas. 2024 @ 19:51

Grąža: -0.13%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 5.65 %

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	454 722
Vidutinė apimtis	428 539
Rinkos kapitalizacija	2.28B
EPS	$0 ( 2024-02-29 )
Kita pelno data	( $-0.110 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-672.57
ATR14	$0.108 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Colangelo Dominick	Buy	6 002	Stock Option (Right to Buy)
2024-04-30	Colangelo Dominick	Buy	13 888	Stock Option (Right to Buy)
2024-04-30	Colangelo Dominick	Buy	5 555	Common Stock
2024-04-30	Colangelo Dominick	Buy	5 555	Stock Option (Right to Buy)
2024-04-30	Colangelo Dominick	Buy	6 002	Common Stock

INSIDER POWER
68.00
Last 100 transactions
Buy: 883 338 \| Sell: 166 323

Tūris Koreliacija

Ilgas: -0.07 (neutral)

Trumpas: -0.56 (weak negative)

Signal:(25.467) Neutral

Vericel Corp Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CSLMU	0.902
CLBT	0.89
ATCX	0.885
BRACU	0.885
CRVL	0.875
CMPO	0.872
ARAY	0.871
CVT	0.866
BYNOU	0.865
EYEN	0.865

10 Labiausiai neigiamai susiję koreliacijos
NAKD	-0.887
TRIT	-0.884
PRPH	-0.88
VIEW	-0.871
RAVN	-0.868
LAWS	-0.86
CHKEL	-0.859
SYBT	-0.856
PROC	-0.855
HTBK	-0.855

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Vericel Corp Koreliacija - Valiuta/Žaliavos

-0.69
( moderate negative )

-0.84
( strong negative )

-0.65
( weak negative )

0.03
( neutral )

0.66
( moderate )

Vericel Corp Finansinės ataskaitos

Annual	2023
Pajamos:	$197.52M
Bruto pelnas:	$135.58M (68.64 %)
EPS:	$-0.0669

FY	2023
Pajamos:	$197.52M
Bruto pelnas:	$135.58M (68.64 %)
EPS:	$-0.0669

FY	2022
Pajamos:	$164.37M
Bruto pelnas:	$109.79M (66.80 %)
EPS:	$-0.350

FY	2021
Pajamos:	$156.18M
Bruto pelnas:	$106.03M (67.88 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.